You are here

Home » CERID Bibliography

CERID Bibliography

Export 26 results:
Author Title Type [ Year(Asc)]
Filters: Keyword is Hepatitis C  [Clear All Filters]
2013
Wilkins C, Woodward J, Lau DT-Y, Barnes A, Joyce M, McFarlane N, McKeating JA, D Tyrrell L, Gale M. IFITM1 is a tight junction protein that inhibits hepatitis C virus entry. Hepatology. 2013 ;57(2):461-9.
Horner SM, Gale M. Regulation of hepatic innate immunity by hepatitis C virus. Nat Med. 2013 ;19(7):879-88.
Ireton RC, Gale M. Systems biology analyses to define host responses to HCV infection and therapy. Curr Top Microbiol Immunol. 2013 ;363:143-67.
2012
Horner SM, Park HSoo, Gale M. Control of innate immune signaling and membrane targeting by the Hepatitis C virus NS3/4A protease are governed by the NS3 helix α0. J Virol. 2012 ;86(6):3112-20.
Patel MR, Loo Y-M, Horner SM, Gale M, Malik HS. Convergent evolution of escape from hepaciviral antagonism in primates. PLoS Biol. 2012 ;10(3):e1001282.
Schnell G, Loo Y-M, Marcotrigiano J, Gale M. Uridine composition of the poly-U/UC tract of HCV RNA defines non-self recognition by RIG-I. PLoS Pathog. 2012 ;8(8):e1002839.
2010
Yuan HJ, Jain M, Snow KK, Gale M, Lee WM. Evolution of hepatitis C virus NS5A region in breakthrough patients during pegylated interferon and ribavirin therapy*. J Viral Hepat. 2010 ;17(3):208-16.
Gottlieb GS, Smith RA, Sow PSalif. Long-term nonprogressive disease among individuals with untreated HIV infection. JAMA. 2010 ;304(16):1784; author reply 1785-6.
2009
Lanford RE, Evans MJ, Lohmann V, Lindenbach B, Gale M, Rehermann B, Chang K-M, Lemon SM. The accelerating pace of HCV research: a summary of the 15th International Symposium on Hepatitis C Virus And Related Viruses. Gastroenterology. 2009 ;136(1):9-16.
Horner SM, Gale M. Intracellular innate immune cascades and interferon defenses that control hepatitis C virus. J Interferon Cytokine Res. 2009 ;29(9):489-98.
Jain MK, Yuan H-J, Adams-Huet B, Reeck A, Shelton J, Attar N, Zhang S, Neumann AU, Carney DS, Gale M, et al. Pegylated interferon and ribavirin promote early evolution of nonstructural 5A protein in individuals with hepatitis C who demonstrate a response to treatment. J Infect Dis. 2009 ;200(6):866-76.
2008
Erickson AK, Seiwert S, Gale M. Antiviral potency analysis and functional comparison of consensus interferon, interferon-alpha2a and pegylated interferon-alpha2b against hepatitis C virus infection. Antivir Ther. 2008 ;13(7):851-62.
Alpers CE, Smith KD. Cryoglobulinemia and renal disease. Curr Opin Nephrol Hypertens. 2008 ;17(3):243-9.
Chapman LE, Sullivent EE, Grohskopf LA, Beltrami EM, Perz JF, Kretsinger K, Panlilio AL, Thompson ND, Ehrenberg RL, Gensheimer KF, et al. Postexposure interventions to prevent infection with HBV, HCV, or HIV, and tetanus in people wounded during bombings and other mass casualty events--United States, 2008: recommendations of the Centers for Disease Control and Prevention and Disaster Medici. Disaster Med Public Health Prep. 2008 ;2(3):150-65.
Chapman LE, Sullivent EE, Grohskopf LA, Beltrami EM, Perz JF, Kretsinger K, Panlilio AL, Thompson ND, Ehrenberg RL, Gensheimer KF, et al. Recommendations for postexposure interventions to prevent infection with hepatitis B virus, hepatitis C virus, or human immunodeficiency virus, and tetanus in persons wounded during bombings and other mass-casualty events--United States, 2008: recommendat. MMWR Recomm Rep. 2008 ;57(RR-6):1-21; quiz CE1-4.
Saito T, Gale M. [RIG-I mediated hepatic innate immune signaling that controls HCV infection]. Uirusu. 2008 ;58(2):105-15.
2007
Loo YM, Gale M. Viral regulation and evasion of the host response. Curr Top Microbiol Immunol. 2007 ;316:295-313.
2006
Loo Y-M, Owen DM, Li K, Erickson AK, Johnson CL, Fish PM, D Carney S, Wang T, Ishida H, Yoneyama M, et al. Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci U S A. 2006 ;103(15):6001-6.
2005
Gale M, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature. 2005 ;436(7053):939-45.
Smith KD, Alpers CE. Pathogenic mechanisms in membranoproliferative glomerulonephritis. Curr Opin Nephrol Hypertens. 2005 ;14(4):396-403.
Lee WM, Polson JE, D Carney S, Sahin B, Gale M. Reemergence of hepatitis C virus after 8.5 years in a patient with hypogammaglobulinemia: evidence for an occult viral reservoir. J Infect Dis. 2005 ;192(6):1088-92.
2004
Tan S-L, He Y, Huang Y, Gale M. Strategies for hepatitis C therapeutic intervention: now and next. Curr Opin Pharmacol. 2004 ;4(5):465-70.
2003
Foy E, Li K, Wang C, Sumpter R, Ikeda M, Lemon SM, Gale M. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science. 2003 ;300(5622):1145-8.
2002
Katze MG, He Y, Gale M. Viruses and interferon: a fight for supremacy. Nat Rev Immunol. 2002 ;2(9):675-87.
2001
Gale M, Beard MR. Molecular clones of hepatitis C virus: applications to animal models. ILAR J. 2001 ;42(2):139-51.

Pages